CA 2024 * | 46,24 Md 49,8 Md 45,09 Md | CA 2025 * | 49,92 Md 53,76 Md 48,68 Md | Capitalisation | 114 Md 123 Md 111 Md |
---|---|---|---|---|---|
Résultat net 2024 * | 7,13 Md 7,68 Md 6,95 Md | Résultat net 2025 * | 8,66 Md 9,32 Md 8,44 Md | VE / CA 2024 * | 2,61 x |
Dette nette 2024 * | 6,56 Md 7,07 Md 6,4 Md | Dette nette 2025 * | 1,95 Md 2,1 Md 1,9 Md | VE / CA 2025 * | 2,32 x |
PER 2024 * |
16,1
x | PER 2025 * |
13,2
x | Employés | - |
Rendement 2024 * |
4,21% | Rendement 2025 * |
4,46% | Flottant | 87,12% |
Dernier transcript sur Sanofi SA
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/09/19 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 01/01/22 |
Chief Tech/Sci/R&D Officer | 51 | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01/05/14 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22/05/20 |
Frédéric Oudéa
CHM | Chairman | 60 | 02/09/22 |
Nom | PEA | Position | Varia. 1 janv. | Notation |
---|---|---|---|---|
ROBECO BP US PREMIUM EQUITIES I $ | Non | 78.47M USD | +7,00% |
Varia. 1 janv. | Capi. | |
---|---|---|
+26,08% | 662 Md | |
+21,85% | 546 Md | |
-4,77% | 359 Md | |
+16,97% | 323 Md | |
+5,69% | 290 Md | |
+13,68% | 234 Md | |
+3,65% | 198 Md | |
-11,12% | 194 Md | |
+8,08% | 167 Md |